Hope and a Plan
Driving research for ALL pancreatic cancer patients
Destroy Pancreatic Cancer aims to fund research that results in significant and measurable improvements in treatment plans and survival rates. A disease as dire as pancreatic cancer needs a team of medical professionals and healthcare organizations that have already proven to be on the cutting edge of pancreatic cancer treatment. By assembling the best pancreatic cancer team in the United States, we believe that a cure is not only possible, it’s inevitable.
Leading the Way
Meet our team and learn how the collaborative relationship coordinated and funded by Destroy Pancreatic Cancer among three leading pancreatic cancer programs will deliver hope for tomorrow and a plan for today’s patients.
Medical College of Wisconsin (MCW)
Pancreatic cancer is one of the most complex and difficult cancers to treat. The best outcomes are the result of accurate diagnosis and careful treatment planning using a team approach. The pancreatic cancer team at Froedtert and The Medical College of Wisconsin includes physicians with an international reputation for research and clinical care. They have highly specialized training in treating cancers of the pancreas, and they provide a wide array of advanced therapies under innovative treatment protocols.
Pancreatic tumors can be very complex, and many patients require several different kinds of treatment, which may include surgery, radiation therapy, drug therapy and participation in clinical trials.
Douglas B. Evans, MD
Douglas B. Evans, MD, is the Donald C. Ausman Family Foundation Professor of Surgery and Chair of the Department of Surgery at The Medical College of Wisconsin. At MCW, Dr. Evans forged the Program in Pancreatic Cancer Research including a clinical database, a tissue bank, a personalized cancer treatment clinical trial and ongoing laboratory research. He authored or co-authored 262 journal articles and has edited seven books. He has delivered more than 70 invited lectureships nationally, most recently at Harvard Medical School, and has been invited to present his research findings at international meetings.
Dr. Evans is the doctor every pancreatic cancer patient deserves. His personal mission is to train and share his knowledge with medical professionals who have dedicated their careers to destroying pancreatic cancer.
TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN)
TGen, an affiliate of City of Hope, is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. Its mission is to save lives by making and translating genomic discoveries into advances in human health. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help patients through the efficiency and effectiveness of the translational process. This collaborative process has led to an increased understanding of genomics that is changing how we approach cancer treatment. For more information, visit tgen.org. Follow TGen on Facebook, LinkedIn and Twitter @TGen.
Daniel D. Von Hoff, MD, FACP
Daniel D. Von Hoff, MD, FACP, is currently Physician in Chief and Director of Translational Research at TGen. He is also Chief Scientific Officer for US Oncology and for HonorHealth’s Clinical Research Institute, and a Clinical Professor of Medicine at the University of Arizona.
Dr. Von Hoff’s major interest is in the development of new anticancer agents. At present, he is concentrating on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers. His clinical trial work has led to the approval of 3 of the 4 drugs approved by the FDA because they improved survival for treatment of patients with advanced pancreatic cancer.
Dr. Von Hoff graduated from Carroll College and received his medical degree from Columbia University College of Physicians and Surgeons. He completed his internship and residency in internal medicine at the University of California, San Francisco, and a fellowship in medical oncology at the National Cancer Institute.
Piedmont Cancer Institute (PCI)
The medical professionals of PCI are true care partners who treat the whole patient. Every cancer is unique, which requires an individualized treatment plan. PCI has dedicated itself to becoming the premier pancreatic cancer program in the Southeast so that diagnosed patients aren’t required to travel for weeks or months at a time to receive world-class care.
PCI develops cutting-edge cancer therapies and participates in clinical trials to bring patients the most extensive resources and comprehensive cancer treatment teams.
W. Perry Ballard, III, MD
Born at the very hospital he now calls his professional home base, Piedmont Hospital in Atlanta, Georgia, W. Perry Ballard, III, MD, has been practicing medicine since he graduated from Emory University School of Medicine in 1978. He completed his internship and residency at New York Hospital – Cornell Medical Center and Memorial Sloan – Kettering Cancer Center. After residency, he completed a yearlong fellowship in Infectious Disease at Tufts – New England Medical Center in Boston, Massachusetts. He then returned to New York, where he completed a three-year fellowship in Hematology and Oncology at Cornell.
In 1987, Dr. Ballard co-founded Piedmont Cancer Institute, P.C. He has been listed as one of the “Top Doctors” in his field in Atlanta Magazine, as well as being listed in the directory of “Best Doctors in America.” He cares for his patients with an authentic sense of compassion and believes that every cancer patient has reason to hope.